Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00468858
Other study ID # A-14040
Secondary ID WIRB number 2007
Status Completed
Phase Phase 2
First received May 1, 2007
Last updated February 1, 2016
Start date July 2007
Est. completion date April 2010

Study information

Verified date February 2016
Source U.S. Army Medical Research and Materiel Command
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and effectiveness of two different formulations of an investigational dengue vaccine (T-DEN) against a placebo vaccine when two doses are given six months apart to adults and children.


Description:

In this study, children and adults at multiple sites in Puerto Rico will be randomly allocated to receive one of two T-DEN formulations or placebo. Subjects will be stratified by age group (a specific number of subjects in each of 4 age groups [12 months to 50 years of age] will be enrolled). The study includes 6 scheduled visits and 4 scheduled venipunctures. Safety follow-up for dengue may require unscheduled visits and venipunctures.

> Multiple DEN virus serotypes are endemic in Puerto Rico and all residents are considered to be at risk for dengue. The results of this phase II study will provide a basis for identifying the vaccine formulations which elicit neutralizing antibodies to all four dengue virus serotypes in a high proportion of vaccine recipients. The most immunogenic and well tolerated candidate formulation identified in this study will be considered for advancement to phase III development.

>


Recruitment information / eligibility

Status Completed
Enrollment 636
Est. completion date April 2010
Est. primary completion date April 2010
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 12 Months to 50 Years
Eligibility Inclusion Criteria:

- Subjects who the investigator believes that they and/or their parents/guardians can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits) should be enrolled in the study.

- A healthy male or non-pregnant female between 12 months (mths) and 50 years (yrs) of age at the time of the first vaccination;

- Free of obvious health problems as established by medical history and physical examination before entering into the study;

- For children: 23mths of age, full compliance with the United States Advisory Committee on Immunization Practices (U.S. ACIP) recommended childhood immunization schedule;

- Written informed consent obtained from the subject or a parent/guardian and assent for subjects 7-20 yrs of age;

- If the subject is female, she must be of non-childbearing potential, i.e. either pre-menarcheal, surgically sterilized or one year post-menopausal; or, if of childbearing potential, she must be abstinent or have used adequate contraceptive precautions (i.e. intrauterine contraceptive device; condom and spermicide combination, oral contraceptives or other equivalent hormonal contraception, e.g. progestin implantable, cutaneous hormonal patch or injectable contraceptives) for 30 days (dys) prior to vaccination, have a negative pregnancy test within 48 hrs prior to vaccination and must agree to continue such precautions for 60 dys after completion of the vaccination series. Any child who begins menarche during the study period must follow the same precautions listed above, from menarche until 60 dys after the second vaccine dose.

Exclusion Criteria:

- Pregnant or lactating female;

- Female planning to become pregnant or planning to discontinue abstinence or contraceptive precautions;

- History of any neurological or behavioral disorder or seizures, with the exception of a single febrile seizure in childhood;

- History of allergic disease/reaction likely to be exacerbated by any component of the vaccine;

- Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic, renal, hematologic or endocrine functional defect, as determined by physical examination or laboratory tests;

- Any confirmed or suspected immunosuppressive or immunodeficient condition;

- Acute disease at the time of enrollment (acute disease is defined as the presence of a moderate or severe illness with or without fever); note that vaccine can be administered to persons with a minor illness such as diarrhea, mild upper respiratory infection with or without low-grade febrile illness, i.e., equivalent to an oral temperature <37.5°C/<99.5°F.

- Chronic hepatomegaly, right upper quadrant abdominal pain or tenderness;

- Chronic splenomegaly, left upper quadrant abdominal pain or tenderness;

- Use of any investigational or non-registered drug or vaccine other than the study vaccine within 30 dys preceding the first dose of study vaccine/placebo or planned use during the study period;

- Planned administration of a vaccine not foreseen by the study protocol during the period starting from 30 dys before each dose of the study vaccine and ending 30 dys after; with the exception of standard infant and children "inactivated" vaccines or the inactivated influenza vaccine administered to adults or children;

- A planned move to a location that will prohibit participating in the trial for the 12 mth duration;

- Chronic administration (defined as more than 14 dys) of immunosuppressants or other immune-modifying drugs within 90 dys preceding the first dose or planned administration during the study period. For corticosteroids, this will mean prednisone, or equivalent, 0.5 mg/kg/day. Inhaled and topical steroids are allowed;

- Administration of immunoglobulins and/or blood products within 90 dys preceding the first dose or planned administration during the study period;

- Hypertension;

- Chest pain, palpitations, dizziness, shortness of breath unrelated to asthma, arrhythmias or friction rubs;

- Any chronic systemic drug therapy to be continued during the study period (except for vitamin/mineral supplements, routine treatment for gastro-esophageal reflux);

- Potential adult volunteers, or parents of potential child volunteers, who do not have easy access to a fixed or mobile telephone;

- History of chronic alcohol consumption and/or drug abuse.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention


Intervention

Other:
Placebo
Lyophilized, single dose vials and sterile water for > injection; 0.5 mL dose; Vaccination schedule: 0, 6 months
Biological:
T-DEN-Post-Transfection F17
Lyophilized, single dose vials and sterile water for injection; 0.5 mL dose at 0 and 6 months
T-DEN-Post-Transfection F19
Lyophilized, single dose vials and sterile water for injection; 0.5 mL dose at 0 and 6 months

Locations

Country Name City State
Puerto Rico San Juan Batista Medical School Caguas
Puerto Rico Private Practice Carolina
Puerto Rico St Luke's Memorial Hospital Ponce
Puerto Rico Caparra Internal Medicine Research Center Rio Grande
Puerto Rico Private Practice Rio Piedras
Puerto Rico RCMI Clinical Research Center Rio Piedras
Puerto Rico Torre Medica San Vicente de Paul San German
Puerto Rico Centro de Neumologia Pediatricia San Juan
Puerto Rico Clinical Research PR San Juan
Puerto Rico Dept Pediatria, Esc. De Medicina San Juan
Puerto Rico Private Practice San Juan

Sponsors (2)

Lead Sponsor Collaborator
U.S. Army Medical Research and Materiel Command GlaxoSmithKline

Country where clinical trial is conducted

Puerto Rico, 

Outcome

Type Measure Description Time frame Safety issue
Primary Occurrence, intensity and relationship to vaccination of any solicited local and general adverse events Within 21 days (days 0-20) f/up period after each vaccine dose Yes
Primary Occurrence, intensity and relationship to vaccination of each type of solicited local and general adverse events Within the 21-day (days 0-20) follow-up period after each vaccine dose Yes
Primary Occurrence, intensity and relationship to vaccination of unsolicited AEs Within the 31-day (days 0-30) follow-up period after each vaccine dose Yes
Primary Occurrence of serious adverse events (SAEs) Throughout the entire study period Yes
Primary N antibody titers to each DEN serotype At month 7 in unprimed subjects No
Secondary Occurence of suspected and laboratory confirmed dengue Throughout the entire study period Yes
Secondary N antibody titer above the assay cut off to each DEN serotype At months 0, 3, 6, and 7 No
Secondary N antibody titer above the assay cut-off to all dengue serotypes At months 0, 3, 6, and 7 No
Secondary N sero-response to each DEN serotype At months 0, 3, 6, and 7 No
Secondary N antibody titer to each DEN serotype At months 0, 3, 6, and 7 No
See also
  Status Clinical Trial Phase
Recruiting NCT04514107 - A Cluster-randomized Trial to EValuate the Efficacy of Wolbachia-InfecTed Aedes Aegypti Mosquitoes in Reducing the Incidence of Arboviral Infection in Brazil (EVITA Dengue) N/A
Completed NCT00788151 - Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years Phase 2
Completed NCT02510638 - The Clinical Epidemiology of Hospitalized Dengue Cases in Malaysia N/A
Completed NCT01666652 - A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults Phase 1
Completed NCT01477671 - Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children N/A
Completed NCT01443247 - Role of Andi-d in Dengue Fever: a Pilot Study N/A
Completed NCT00831012 - Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3delta30/31‐7164) in Healthy Adults Phase 1
Completed NCT00089908 - Safety of and Immune Response to a Dengue Virus Vaccine (rDEN1delta30) in Healthy Adults Phase 1
Completed NCT01983553 - Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study
Completed NCT01134263 - Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia Phase 3
Completed NCT02741128 - Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults Phase 2
Completed NCT03620487 - Detection of Dengue Virus in Plasma of Patients in Nepal
Recruiting NCT02608047 - Studies on the Pathogen, Vector Control and Clinical Treatment of Dengue Fever in Guangzhou N/A
Completed NCT02510690 - Factors Associated With Poor Dengue Outcomes in Malaysia N/A
Completed NCT01550016 - International Research Consortium on Dengue Risk Assessment, Management, and Surveillance N/A
Completed NCT01421732 - Laboratory Diagnosis and Prognosis of Severe Dengue N/A
Completed NCT00993447 - Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America Phase 2
Completed NCT01224639 - Safety and Immunogenicity Study to Assess TDV, a Live Attenuated Tetravalent Vaccine for Prevention of Dengue Fever Phase 1
Completed NCT01943825 - Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine Phase 2
Active, not recruiting NCT03465254 - Dengue Serostatus Study in the Philippines